Get the Stockscreener App
3.695
0.67%
-0.025
After Hours:
3.68
-0.015
-0.41%
Aquestive Therapeutics Inc stock is traded at $3.695, with a volume of 1.79M.
It is down -0.67% in the last 24 hours and down -11.18% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.72
Open:
$3.75
24h Volume:
1.79M
Relative Volume:
0.97
Market Cap:
$463.60M
Revenue:
$50.27M
Net Income/Loss:
$-68.91M
P/E Ratio:
-6.1277
EPS:
-0.603
Net Cash Flow:
$-44.32M
1W Performance:
+0.41%
1M Performance:
-11.18%
6M Performance:
+25.25%
1Y Performance:
-3.78%
1-Day Range:
$3.605
$3.78
1-Week Range:
$3.56
$3.86
52-Week Range:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.695 | 467.99M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey
AQST|Aquestive Therapeutics Inc|Price:3.680|Chg%:-0.090 - TradingKey
Aquestive Therapeutics Inc (AQST) Balance Sheet - TradingKey
2026-07-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Inc (AQST) Cash Flow - TradingKey
Aquestive Therapeutics Inc (AQST) Income Statement - TradingKey
Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
ETFs Investing in Aquestive Therapeutics, Inc. Stocks - TradingView
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Price to book forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Enterprise value to EBITDA forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Price to sales forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Enterprise value to revenue forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Form 4 Aquestive Therapeutics Inc For: 17 July By Investing.com - Investing.com South Africa
Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE - GuruFocus
Aquestive Therapeutics president and CEO Daniel Barber sells $100,191 in stock - Investing.com Canada
Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04 - Stock Titan
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $100,201.97 - Bitget
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review
2026-07-16 | Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review
Form 144 Aquestive Therapeutics For: 15 July By Investing.com - Investing.com South Africa
Price to earnings forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics (AQST) Faces Selling Pressure, Tests Support Near $3.91Cash Flow Strong Stocks - dars.gov.et
2026-07-12 | Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
Aquestive Therapeutics, Inc. SEC Filing (Jul 9, 2026) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - Investing News Network
Aquestive Therapeutics to present at Leerink Pa... - Pluang
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
2026-07-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
AQSTAquestive Therapeutics Inc Short Interest - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barber Daniel | President and CEO |
Jul 15 '26 |
Sale |
4.03 |
4,631 |
18,683 |
630,943 |
2.08%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):